Stoke Therapeutics, Inc. (STOK) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $33.22 (+1.51%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 5, 2026 | Yatin Suneja | Guggenheim | $60.00 | +80.6% |
| Jan 5, 2026 | Keay Nakae | Loop Capital Markets | $35.00 | +5.4% |
| Dec 16, 2025 | Andrew Fein | H.C. Wainwright | $50.00 | +50.5% |
| Aug 18, 2025 | Thomas Shrader | BTIG | $28.00 | -15.7% |
| Oct 11, 2024 | Marc Goodman | Leerink Partners | $18.00 | -45.8% |
| Sep 11, 2024 | Debjit Chattopadhyay | H.C. Wainwright | $35.00 | +5.4% |
| May 7, 2024 | Sumant Kulkami | Canaccord Genuity | $20.00 | -39.8% |
| Mar 26, 2024 | Joseph Stringer | Needham | $22.00 | -33.8% |
| Mar 26, 2024 | Sumant Kulkami | Canaccord Genuity | $21.00 | -36.8% |
| Apr 26, 2021 | Judah Frommer | Credit Suisse | $58.00 | +74.6% |
Top Analysts Covering STOK
STOK vs Sector & Market
| Metric | STOK | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.07 | 2.24 | 2.41 |
| Analyst Count | 14 | 8 | 18 |
| Target Upside | +32.0% | +1150.2% | +14.9% |
| P/E Ratio | -282.66 | 7.13 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $5M | $7M | $8M | 6 |
| 2026-09-30 | $6M | $7M | $8M | 4 |
| 2026-12-31 | $6M | $8M | $9M | 5 |
| 2027-03-31 | $5M | $6M | $6M | 3 |
| 2027-06-30 | $5M | $6M | $6M | 3 |
| 2027-09-30 | $5M | $6M | $6M | 3 |
| 2027-12-31 | $5M | $6M | $6M | 3 |
| 2028-12-31 | $121M | $124M | $127M | 9 |
| 2029-12-31 | $161M | $335M | $540M | 4 |
| 2030-12-31 | $263M | $547M | $881M | 4 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $-0.97 | $-0.81 | $-0.57 | 6 |
| 2026-09-30 | $-1.03 | $-0.85 | $-0.68 | 3 |
| 2026-12-31 | $-1.09 | $-0.90 | $-0.72 | 4 |
| 2027-03-31 | $-1.09 | $-0.90 | $-0.72 | 2 |
| 2027-06-30 | $-1.10 | $-0.92 | $-0.73 | 2 |
| 2027-09-30 | $-1.04 | $-0.86 | $-0.68 | 2 |
| 2027-12-31 | $-0.97 | $-0.81 | $-0.64 | 2 |
| 2028-12-31 | $-3.43 | $-2.15 | $-0.69 | 8 |
| 2029-12-31 | $0.03 | $0.08 | $0.15 | 6 |
| 2030-12-31 | $0.58 | $1.78 | $3.20 | 6 |
Frequently Asked Questions
What is the analyst consensus for STOK?
The consensus among 14 analysts covering Stoke Therapeutics, Inc. (STOK) is Buy with an average price target of $42.75.
What is the highest price target for STOK?
The highest price target for STOK is $60.00, set by Yatin Suneja at Guggenheim on 2026-02-05.
What is the lowest price target for STOK?
The lowest price target for STOK is $18.00, set by Marc Goodman at Leerink Partners on 2024-10-11.
How many analysts cover STOK?
14 analysts have issued ratings for Stoke Therapeutics, Inc. in the past 12 months.
Is STOK a buy or sell right now?
Based on 14 analyst ratings, STOK has a consensus rating of Buy (2.07/5) with a +32.0% upside to the consensus target of $42.75.
What are the earnings estimates for STOK?
Analysts estimate STOK will report EPS of $-0.81 for the period ending 2026-06-30, with revenue estimated at $7M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.